Compare Stocks → Your Money is Not Safe (From American Alternative) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BGXXNASDAQ:CDXCNASDAQ:MNMD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGXXBright Green$0.22$0.24$0.15▼$1.81$40.09M0.721.78 million shs424,272 shsCDXCChromaDex$3.79-4.5%$2.62$1.25▼$4.65$285.43M1.99253,582 shs199,115 shsMNMDMind Medicine (MindMed)$8.91-6.5%$7.98$2.41▼$12.22$626.11M2.811.96 million shs1.65 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGXXBright Green+2.11%-7.25%-21.43%-17.56%-85.26%CDXCChromaDex-4.53%-7.33%+39.85%+170.71%+163.19%MNMDMind Medicine (MindMed)-6.51%-13.07%-8.99%+148.19%+133.86%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/ACDXCChromaDex3.8447 of 5 stars3.52.00.04.13.50.80.6MNMDMind Medicine (MindMed)1.6396 of 5 stars3.52.00.00.02.60.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGXXBright GreenN/AN/AN/AN/ACDXCChromaDex3.00Buy$5.8754.79% UpsideMNMDMind Medicine (MindMed)3.00Buy$25.20182.83% UpsideCurrent Analyst RatingsLatest BGXX, CDXC, and MNMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024MNMDMind Medicine (MindMed)Leerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/15/2024MNMDMind Medicine (MindMed)SVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.004/9/2024CDXCChromaDexRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.25 ➝ $6.003/14/2024MNMDMind Medicine (MindMed)HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.003/1/2024MNMDMind Medicine (MindMed)HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.002/29/2024MNMDMind Medicine (MindMed)Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$14.00 ➝ $15.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGXXBright GreenN/AN/AN/AN/A$0.07 per shareN/ACDXCChromaDex$83.57M3.42N/AN/A$0.38 per share9.97MNMDMind Medicine (MindMed)N/AN/AN/AN/A$1.90 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGXXBright Green-$27.66M-$0.08N/A∞N/AN/A-73.26%-39.82%5/27/2024 (Estimated)CDXCChromaDex-$4.94M-$0.07N/A63.17N/A-5.91%-17.81%-9.17%5/8/2024 (Estimated)MNMDMind Medicine (MindMed)-$95.73M-$2.45N/AN/AN/AN/A-89.72%-65.33%5/2/2024 (Estimated)Latest BGXX, CDXC, and MNMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023MNMDMind Medicine (MindMed)-$0.48-$0.59-$0.11-$0.59N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGXXBright GreenN/AN/AN/AN/AN/ACDXCChromaDexN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGXXBright GreenN/A0.030.03CDXCChromaDexN/A2.401.70MNMDMind Medicine (MindMed)0.183.223.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGXXBright Green7.83%CDXCChromaDex15.41%MNMDMind Medicine (MindMed)27.91%Insider OwnershipCompanyInsider OwnershipBGXXBright Green51.38%CDXCChromaDex10.57%MNMDMind Medicine (MindMed)2.11%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBGXXBright Green23183.88 million89.40 millionOptionableCDXCChromaDex10675.31 million67.35 millionOptionableMNMDMind Medicine (MindMed)5770.27 million68.79 millionOptionableBGXX, CDXC, and MNMD HeadlinesSourceHeadlineMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 2.9%marketbeat.com - April 18 at 3:41 PMLeerink Partnrs Reaffirms Outperform Rating for Mind Medicine (MindMed) (NASDAQ:MNMD)americanbankingnews.com - April 18 at 2:02 AMAnalysts Set Expectations for Mind Medicine (MindMed) Inc.'s Q1 2024 Earnings (NASDAQ:MNMD)americanbankingnews.com - April 18 at 1:28 AMLeerink Partnrs Weighs in on Mind Medicine (MindMed) Inc.'s Q1 2024 Earnings (NASDAQ:MNMD)marketbeat.com - April 17 at 4:48 PMLeerink Partnrs Reaffirms "Outperform" Rating for Mind Medicine (MindMed) (NASDAQ:MNMD)marketbeat.com - April 17 at 4:40 PMMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 3.1%marketbeat.com - April 17 at 1:11 PMMind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap Up to $9.67americanbankingnews.com - April 17 at 5:15 AMLeerink Partners Initiates Coverage of Mind Medicine (MNMD) with Outperform Recommendationmsn.com - April 16 at 10:36 AMMind Medicine (MindMed) (NASDAQ:MNMD) Coverage Initiated by Analysts at SVB Leerinkamericanbankingnews.com - April 16 at 4:50 AMMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Short Interest Up 23.2% in Marchmarketbeat.com - April 15 at 9:35 PMSVB Leerink Initiates Coverage on Mind Medicine (MindMed) (NASDAQ:MNMD)marketbeat.com - April 15 at 8:35 AMMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 3.2%americanbankingnews.com - April 14 at 3:56 AMMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 6.5%marketbeat.com - April 11 at 2:49 PMMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 7.3%marketbeat.com - April 10 at 1:39 PMMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Rating of "Buy" from Analystsamericanbankingnews.com - April 10 at 2:16 AMMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Average Recommendation of "Buy" by Analystsmarketbeat.com - April 10 at 2:14 AMMind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 5.4% marketbeat.com - April 9 at 12:54 PMMind Medicine (MindMed) (NASDAQ:MNMD) Trading 3.2% Higher marketbeat.com - April 8 at 12:46 PMMindMed (MNMD) Stock Rises 154% in 3 Months: Here's Whyzacks.com - April 8 at 8:01 AMMind Medicine (MindMed) (NASDAQ:MNMD) Trading 1.5% Higher marketbeat.com - April 5 at 1:49 PMMind Medicine: GAD Program Success Continues With BTD And Positive Treatment Dataseekingalpha.com - April 4 at 1:30 PMMind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap Up to $11.75marketbeat.com - April 4 at 1:20 PMThree Stocks: MindMed, Ulta, and Intelmoneymorning.com - April 4 at 3:29 AMMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 20.2%marketbeat.com - April 3 at 3:49 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBright GreenNASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.ChromaDexNASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Mind Medicine (MindMed)NASDAQ:MNMDMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.